Iovance Biotherapeutics, Inc.
IOVA
$6.98
$0.467.06%
NASDAQ
Recommendation
Dividend Power Score
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
P/E (TTM)
--
EPS (TTM)
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 34.55% | 34.29% | 60.60% | 175.62% | 636.99% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 34.55% | 34.29% | 60.60% | 175.62% | 636.99% |
| Cost of Revenue | 4.21% | 20.63% | 60.45% | 125.28% | 239.93% |
| Gross Profit | 95.09% | 62.57% | 60.90% | 405.10% | 653.65% |
| SG&A Expenses | -8.49% | -10.64% | -0.19% | 12.87% | 27.53% |
| Depreciation & Amortization | 0.73% | 35.12% | 90.31% | 265.58% | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -4.76% | 5.26% | 18.30% | 27.06% | 32.55% |
| Operating Income | 27.88% | 10.22% | -0.74% | 4.33% | 10.59% |
| Income Before Tax | 24.62% | 6.30% | -4.81% | 4.28% | 12.63% |
| Income Tax Expenses | -2,365.43% | 72.44% | 26.77% | 88.66% | 103.20% |
| Earnings from Continuing Operations | 25.75% | 5.73% | -5.05% | 3.02% | 11.43% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 25.75% | 5.73% | -5.05% | 3.02% | 11.43% |
| EBIT | 27.88% | 10.22% | -0.74% | 4.33% | 10.59% |
| EBITDA | 30.20% | 10.88% | -1.25% | 7.09% | 13.44% |
| EPS Basic | 41.20% | 23.00% | 13.67% | 19.63% | 27.10% |
| Normalized Basic EPS | 42.55% | 26.18% | 16.50% | 20.24% | 26.76% |
| EPS Diluted | 41.20% | 23.00% | 13.67% | 19.63% | 27.10% |
| Normalized Diluted EPS | 42.55% | 26.18% | 16.50% | 20.24% | 26.76% |
| Average Basic Shares Outstanding | 29.57% | 25.35% | 23.22% | 19.46% | 20.21% |
| Average Diluted Shares Outstanding | 29.57% | 25.35% | 23.22% | 19.46% | 20.21% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |